Peptide YY (1-36)
Also known as: Full-length PYY, Peptide YY, PYY, PYY 1-36, PYY(1-36)
Source Peptide YY (1-36) at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Peptide YY (1-36) is an endogenous 36‑amino‑acid hormone released post‑prandially from intestinal L‑cells; it modulates satiety via Y2 receptor activation.
Mechanism of Action
Agonist of neuropeptide Y Y1/Y2 receptors; reduces appetite and slows gastric emptying
Routes of Administration
Goals & Uses
- Pancreatic exocrine secretion inhibitionGastrointestinalLow
- Obesity research biomarkerResearch / MetabolicModerate
- Type 2 diabetes adjunctMetabolicLow
- Obesity treatmentMetabolicModerate
- Gastrointestinal motility reduction (ileal brake)GastrointestinalModerate
- Appetite and satiety modulationMetabolic / EndocrineModerate
Contraindications
- Known hypersensitivity to PYY or excipientsImmunologicHigh
- Clinical therapeutic use outside approved trialsRegulatoryHigh
Adverse Effects
- Injection site reactionsLocalUncommon
- Reduced gastric motility / delayed gastric emptyingGastrointestinalCommon
- HypotensionCardiovascularUncommonLow blood pressure
- NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
- Abdominal painGastrointestinalUncommonPain or discomfort in the abdomen
Drug Interactions
- DPP-IV inhibitors (e.g., sitagliptin, saxagliptin)Moderate
- GLP‑1 receptor agonistsModerate
- Neuropeptide Y receptor antagonistsModerate
Population Constraints
- Pediatric populationsAgeRelative
- PediatricAgeRelative
- Patients with severe gastrointestinal dysmotilityGastrointestinalRelative
- Pregnant womenReproductiveRelative
Regulatory Status
- European UnionUnapprovedNo marketing authorization
- United StatesUnapprovedInvestigational use only
- United KingdomUnapprovedNo MHRA approval; utilized in academic and clinical research settings.
Not approved as a therapeutic agent; investigated in clinical trials for obesity and metabolic disorders.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Peptide YY (1-36)?
Peptide YY (1-36) is an endogenous 36‑amino‑acid hormone released post‑prandially from intestinal L‑cells; it modulates satiety via Y2 receptor activation.
What is Peptide YY (1-36) used for?
Peptide YY (1-36) is educationally associated with: Pancreatic exocrine secretion inhibition, Obesity research biomarker, Type 2 diabetes adjunct, Obesity treatment, Gastrointestinal motility reduction (ileal brake), Appetite and satiety modulation. Educational only — not medical advice.
How is Peptide YY (1-36) administered?
Recorded routes of administration: Intranasal, Intravenous, Subcutaneous.
What are the potential side effects of Peptide YY (1-36)?
Reported adverse effects include: Injection site reactions, Reduced gastric motility / delayed gastric emptying, Hypotension, Nausea, Abdominal pain. This list is not exhaustive — consult a qualified clinician.
Who should avoid Peptide YY (1-36)?
Recorded contraindications: Known hypersensitivity to PYY or excipients, Clinical therapeutic use outside approved trials. Consult a qualified clinician before use.